No Data
An alternative "going abroad" for centralized procurement of pharmaceuticals and medical devices? The China-ASEAN regional centralized procurement platform for pharmaceuticals has been launched, and the industry anticipates the birth of the first Order.
① Today, the China-ASEAN pharmaceutical regional procurement platform officially launched, with representatives from Shenzhen Mindray Bio-Medical Electronics, United Imaging Healthcare, SIMCERE PHARMA, and other companies present; ② Although the specific implementation plan is yet to be clarified, the industry believes it is undoubtedly Bullish for domestic pharmaceutical companies; ③ The Southeast Asian pharmaceutical market is growing rapidly, but it relies heavily on imported drugs and medical devices.
Hong Kong stocks moved differently | Most CRO Concept stocks rose, the momentum for the development of biopharmaceuticals continues, UBS Group is Bullish on the recent earnings prospects of the CRO Industry.
Most CRO concept stocks have risen. As of the time of writing, WUXI BIO (02269) is up 3.28% at HKD 17.02; WUXI APPTEC (02359) is up 3.03% at HKD 52.65; PHARMARON (03759) is up 1.72% at HKD 13.02; Asymchem Laboratories (06821) is up 1.16% at HKD 47.85.
China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk
WUXI BIO sells overseas Assets, but not because of the biosecurity legislation.
By adjusting the Assets, WUXI BIO has released more space and will further increase its overseas investments.
[Brokerage Focus] Morgan Stanley reiterates the "Shareholding" rating for WUXI BIO (02269), indicating that the sale of the Haierland facility is beneficial for profitability and ROI.
Jinwu Finance | Morgan Stanley's research report indicates that since the ROI of this asset for WUXI BIO (02269) is below the target, according to the management of WUXI APPTEC, the trade seems to be a win-win situation for both parties. The company's other facilities in Ireland maintain stable operations, with a gross margin of about 40% in the stable phase. Regarding the use of cash earnings, WUXI APPTEC will further buy back shares and invest in higher return opportunities. As the ROI is performing well, there are currently no other assets that need to be sold. The firm expressed that although selling assets will sacrifice the short-term income of WUXI BIO, it believes this trade will be beneficial to the public.
WuXi Biologics (Cayman) Subsidiary to Sell Vaccines Manufacturing Facility in Ireland for $500 Million
No Data
